According to data [26], EpCAM functioning as a Wnt-beta-catenin signaling target gene may be utilized to promote prognosis of HCC by facilitating efficient stratification of patients with predicted pharmacologic responses to Wnt-beta-catenin signaling antagonists. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.